Certara (NASDAQ:CERT) Shares Gap Up to $20.56

Certara, Inc. (NASDAQ:CERT – Get Rating) shares gapped up prior to trading on Thursday . The stock had previously closed at $20.56, but opened at $21.91. Certara shares last traded at $22.73, with a volume of 758,360 shares traded.

Analyst Upgrades and Downgrades

CERT has been the subject of several recent research reports. Robert W. Baird lowered Certara from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $17.00 to $19.00 in a research report on Wednesday, December 14th. Morgan Stanley lifted their price target on Certara from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Friday, March 10th. Credit Suisse Group lifted their price target on Certara from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, March 2nd. Finally, Barclays boosted their target price on Certara from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, March 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Certara presently has an average rating of “Moderate Buy” and a consensus target price of $22.43.

Certara Stock Down 1.7 %

The company has a debt-to-equity ratio of 0.27, a current ratio of 3.32 and a quick ratio of 3.32. The stock has a market cap of $3.57 billion, a PE ratio of 248.92, a price-to-earnings-growth ratio of 1.88 and a beta of 1.45. The business has a fifty day moving average of $19.18 and a 200-day moving average of $16.22.

Certara (NASDAQ:CERT – Get Rating) last announced its quarterly earnings results on Wednesday, March 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.01). The firm had revenue of $86.60 million during the quarter, compared to analysts’ expectations of $82.55 million. Certara had a net margin of 4.39% and a return on equity of 5.97%. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.38 earnings per share for the current year.

Hedge Funds Weigh In On Certara

A number of large investors have recently bought and sold shares of CERT. OLD Mission Capital LLC bought a new position in Certara in the fourth quarter worth approximately $49,000. Wells Fargo & Company MN raised its stake in Certara by 12.4% in the fourth quarter. Wells Fargo & Company MN now owns 5,325 shares of the company’s stock worth $86,000 after buying an additional 586 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Certara in the third quarter worth approximately $95,000. Captrust Financial Advisors raised its stake in Certara by 135.8% in the first quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock worth $99,000 after buying an additional 2,665 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new position in Certara in the first quarter worth approximately $111,000. Institutional investors own 75.45% of the company’s stock.

About Certara

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.